Effects of liraglutide combined with metformin and Diamicron on glucose–lipid metabolism and islet β-cell function in elderly patients with type 2 diabetes mellitus

References

• Al-Omary FAM. 2017. Gliclazide. Profiles Drug Subst Excip Relat Methodol. 42:125–192. eng.
   Google Scholar
• Ayers D, Kanters S, Goldgrub R, Hughes M, Kato R, Kragh N. 2017. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients. Curr Med Res Opin. 33(9):1653–1661. eng.
   PubMed Web of Science ®Google Scholar
• Colagiuri S, Matthews D, Leiter LA, Chan SP, Sesti G, Marre M. 2018. The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents. Diabetes Res Clin Pract. 143:1–14. eng.
   PubMed Web of Science ®Google Scholar
• Collier A, Meney C, Hair M, Cameron L, Boyle JG. 2020. Cancer has overtaken cardiovascular disease as the commonest cause of death in Scottish type 2 diabetes patients: A population-based study (the ayrshire diabetes follow-up cohort study). J Diabetes Investig. 11(1):55–61. eng.
   Web of Science ®Google Scholar
• DeFronzo RA. 2004. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 88(4):787–835, ix. eng.
   PubMed Web of Science ®Google Scholar
• Duncan BB, Schmidt MI, Ewerton C, Moradi-Lakeh M, Passos VMA, França EB, Marinho F, Mokdad AH. 2017. The burden of diabetes and hyperglycemia in Brazil-past and present: findings from the global burden of disease study 2015. Diabetol Metab Syndr. 9:18. eng.
   Web of Science ®Google Scholar
• Eraky SM, Abdel-Rahman N, Eissa LA. 2018. Modulating effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through toll-like receptor 4 in type 2 diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids. 136:123–129. eng.
   Web of Science ®Google Scholar
• Hagon-Traub I, Chinet L, Georges A, Schlüter V. 2020. [Cantonal diabetes program - a response at local level to address public health issues related to non-communicable diseases]. Rev Med Suisse. 16(682):366–369.. fre.
   Google Scholar
• Huang Q, Liu C, Li JR, Zhang L, Huang FC, Wang D, Luo YJ. 2019. Incremental effect of liraglutide on traditional insulin injections in rats with type 2 diabetes mellitus by maintaining glycolipid metabolism and cardiovascular function. Exp Ther Med. 17(3):1863–1869. eng.
   Web of Science ®Google Scholar
• Kalra S, Das AK. 2017. Epidemiologic surveillance of glycemic response to a scored, breakable, extended release, fixed dose combination of gliclazide and metformin in persons with type 2 diabetes. J Assoc Physicians India. 65(6):38–41. eng.
   Google Scholar
• Ko SH, Hur KY, Rhee SY, Kim NH, Moon MK, Park SO, Lee BW, Kim HJ, Choi KM, Kim JH. 2017. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean diabetes association. Diabetes Metab J. 41(5):337–348. eng.
   Web of Science ®Google Scholar
• Larsson SC, Wallin A, Håkansson N, Stackelberg O, Bäck M, Wolk A. 2018. Type 1 and type 2 diabetes mellitus and incidence of seven cardiovascular diseases. Int J Cardiol. 262:66–70. eng.
   PubMed Web of Science ®Google Scholar
• Ma RCW. 2018. Epidemiology of diabetes and diabetic complications in China. Diabetologia. 61(6):1249–1260. eng.
   PubMed Web of Science ®Google Scholar
• Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB. 2017. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 377(9):839–848. eng.
   PubMed Web of Science ®Google Scholar
• Matikainen N, Söderlund S, Björnson E, Pietiläinen K, Hakkarainen A, Lundbom N, Taskinen MR, Borén J. 2019. Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study. Diabetes Obes Metab. 21(1):84–94. eng.
   PubMed Web of Science ®Google Scholar
• Miao X, Gu Z, Liu Y, Jin M, Lu Y, Gong Y, Li L, Li C. 2018. The glucagon-like peptide-1 analogue liraglutide promotes autophagy through the modulation of 5'-AMP-activated protein kinase in INS-1 β-cells under high glucose conditions. Peptides. 100:127–139. eng.
   PubMed Web of Science ®Google Scholar
• Overbeek JA, Heintjes EM, Prieto-Alhambra D, Blin P, Lassalle R, Hall GC, Lapi F, Bianchini E, Hammar N, Bezemer ID, et al. 2017. Type 2 diabetes mellitus treatment patterns across Europe: A population-based multi-database study. Clin Ther. 39(4):759–770. eng.
   PubMed Web of Science ®Google Scholar
• Peradze N, Farr OM, Perakakis N, Lázaro I, Sala-Vila A, Mantzoros CS. 2019. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial. Cardiovasc Diabetol. 18(1):141. eng.
   Web of Science ®Google Scholar
• Pokala N, Adams-Huet B, Li X, Harrison LB, Vanderheiden A, Lingvay I. 2017. The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. Diabetes Obes Metab. 19(10):1454–1457. eng.
   Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. 2017. The mechanisms of action of metformin. Diabetologia. 60(9):1577–1585. eng.
   PubMed Web of Science ®Google Scholar
• Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. 2017. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 20(1):6–12. eng.
   PubMed Web of Science ®Google Scholar
• Sanchez-Rangel E, Inzucchi SE. 2017. Metformin: clinical use in type 2 diabetes. Diabetologia. 60(9):1586–1593. eng.
   PubMed Web of Science ®Google Scholar
• Sohail MU, Althani A, Anwar H, Rizzi R, Marei HE. 2017. Role of the gastrointestinal tract microbiome in the pathophysiology of diabetes mellitus. J Diabetes Res. 2017:9631435. eng.
   Web of Science ®Google Scholar
• Strain WD, Hope SV, Green A, Kar P, Valabhji J, Sinclair AJ. 2018. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty. A national collaborative stakeholder initiative. Diabet Med. 35(7):838–845. eng.
   Web of Science ®Google Scholar
• Xu Y, Niu Y, Gao Y, Wang F, Qin W, Lu Y, Hu J, Peng L, Liu J, Xiong W. 2017. Borapetoside E, a clerodane diterpenoid extracted from tinospora crispa, improves hyperglycemia and hyperlipidemia in high-Fat-diet-induced type 2 diabetes mice. J Nat Prod. 80(8):2319–2327. eng.
   Web of Science ®Google Scholar
• Yu X, Xu L, Zhou Q, Wu S, Tian J, Piao C, Guo H, Zhang J, Li L, Wu S, et al. 2018. The efficacy and safety of the Chinese herbal formula, JTTZ, for the treatment of type 2 diabetes with obesity and hyperlipidemia: A multicenter randomized, positive-controlled, open-label clinical trial. Int J Endocrinol. 2018:9519231. eng.
   Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. 2018. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 14(2):88–98. eng.
   PubMed Web of Science ®Google Scholar